| Autor: |
Abbott, I. J., Jenney, A. W. J., Jeremiah, C. J., Mirčeta, M., Kandiah, J. P., Holt, D. C., Tong, S. Y. C., Spelman, D. W. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; September 2015, Vol. 59 Issue: 12 p7837-7841, 5p |
| Abstrakt: |
ABSTRACTA total of 421 methicillin-resistant Staphylococcus aureus(MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P< 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
